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NF1 inactivation occurs in specific hu-
man cancers, including juvenile my-
elomonocytic leukemia, an aggressive
myeloproliferative disorder of childhood.
However, evidence suggests that Nf1 loss
alone does not cause leukemia. We there-
fore hypothesized that inactivation of the
Nf1 tumor suppressor gene requires coop-
erating mutations to cause acute leuke-
mia. To search for candidate genes that
cooperate with Nf1 deficiency in leukemo-
genesis, we performed a forward genetic
screen using retroviral insertion mutagen-
esis in Nf1 mutant mice. We identified
43 common proviral insertion sites that
contain candidate genes involved in leu-
kemogenesis. One of these genes, Bcl11a,
confers a growth advantage in cultured
Nf1 mutant hematopoietic cells and
causes early onset of leukemia of either
myeloid or lymphoid lineage in mice when
expressed in Nf1-deficient bone marrow.
Bcl11a-expressing cells display compro-
mised p21Cip1 induction, suggesting that
Bcl11a’s oncogenic effects are mediated,
in part, through suppression of p21Cip1.
Importantly, Bcl11a is expressed in hu-
man chronic myelomonocytic leukemia
and juvenile myelomonocytic leukemia
samples. A subset of AML patients, who
had poor outcomes, of 16 clusters, dis-
played high levels of BCL11A in leukemic
cells. These findings suggest that deregu-
lated Bcl11a cooperates with Nf1 in leuke-
mogenesis, and a therapeutic strategy
targeting the BCL11A pathway may prove
beneficial in the treatment of leukemia.
(Blood. 2009;113:1075-1085)
Introduction
Neurofibromatosis type 1 syndrome (NF1) is an inherited disease
caused by germline mutations of the NF1 gene.1 NF1 encodes
neurofibromin, a GTPase-activating protein that negatively regu-
lates N-, H-, K-, and R-RAS signaling.2 Loss of NF1 function
results in elevated Ras-GTP levels in neoplastic cells of patients
with NF1.3,4 Thus, NF1 deficiency has been proposed to be
functionally equivalent to activation of a RAS oncogene. Neurofi-
bromin may have additional roles in growth control.5-8 Thus,
further investigations into pathways altered in NF1-associated
malignancies may shed light on these mechanisms.
Children with NF1 syndrome show a markedly increased
incidence of myeloid malignancies, particularly juvenile my-
elomonocytic leukemia (JMML), which can further progress
into acute myeloid leukemia (AML).9 Similarly, mice with a
germline Nf1 mutation manifest some phenotypes of NF1
disease and thus provide a tractable model for investigating
NF1-associated complications.10 Notably, evolution to AML is
not observed in mice bearing mutant Nf1 alone. Instead, murine
data from competitive repopulation experiments11 and the long
latency of myeloid disease observed in recipients transplanted
with Nf1/ fetal liver cells12 support the possibility that a
Nf1/ leukemia-initiating cell must acquire one or more
additional mutations to cause leukemia. However, little is
known about the nature of these genetic abnormalities. We
therefore set out to identify genetic events cooperating with
inactivation of Nf1 in leukemogenesis.
The B-cell leukemia 11A gene (BCL11A/Evi9/CTIP1) is essen-
tial for normal lymphoid development13 and has been associated
with hematologic malignancies.14,15 The BCL11A gene was initially
identified from aberrant chromosomal translocations involving the
immunoglobulin heavy chain locus detected in B-cell non-Hodgkin
lymphomas.14 It encodes a Kru¨ppel-like zinc-finger protein contain-
ing 3 C2H2 zinc finger motifs, a proline-rich region, and an acidic
domain. BCL11A functions as a transcriptional regulator via
directly binding to a guanine cytosine (GC)–rich DNA motif.
BCL11A is expressed predominantly in brain, spleen, and testis and
is down-regulated in a leukemia cell line under induction of
myeloid differentiation.16
BXH-2 mice have proven to be a powerful model system to
identify genetic lesions causally associated with leukemia.17
Approximately 15% of BXH-2 myeloid leukemias have proviral
insertions at ecotropic viral integration site 2 (Evi2), all of
which are located within a single large intron of the Nf1 gene.18
Consequently, Nf1 gene function is disrupted, and no wild-type
gene product could be detected in Evi2-bearing leukemias.19
These studies support the idea that BXH-2 AML is an ex-
cellent system to explore the mechanisms of Nf1-associated
leukemia.
We performed a genetic screen in the BXH-2 AML model using
retroviral insertion mutagenesis to search for cooperating genetic
events in Nf1-associated myeloid leukemia. Here we report isola-
tion of 43 common insertion sites (CISs). One such CIS, Evi9, is
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associated with Nf1-deficient BXH-2 AML and targets Bcl11a. We
found that overexpression of Bcl11a causes leukemia in mice under
the condition of Nf1 deficiency. Bcl11a also promotes cell growth
and suppresses p21Cip1 induction. High expression levels of Bcl11a
are seen in certain subsets of AML patients.
Methods
Cell culture and mice
The Nf1-deficient and Nf1-proficient mouse hematopoietic cells immortal-
ized with RED-Myb were maintained in the ASM media.12,20,21 The 293T
were purchased from the ATCC (Manassas, VA) and maintained in
Dulbecco modified Eagle medium (DMEM), supplemented with heat-
inactivated 10% fetal bovine serum and 1% penicillin/streptomycin. Cell
counts were determined manually using a hemocytometer (Reichert,
Buffalo, NY). For all the studies described herein, cells growing in the
logarithmic phase of growth were used. The Nf1(flox/) and Nf1(Fcr/) mouse
lines have been previously described.22,23 The C57BL/6J and C57BL/
6J.BoyJ strain of mouse was purchased from the National Cancer Institute
(Bethesda, MD). Mice were housed, bred, and manipulated under specific
pathogen-free conditions, following the University of Minnesota’s regula-
tions on institutional animal care for research use.
Patient samples
The JMML and chronic myelomonocytic leukemia patient samples used in
this study were obtained following protocols approved by the University of
Minnesota Internal Review Board, with informed consent obtained in
accordance with the Declaration of Helsinki.
Isolation of proviral integration sites
A total of 2 g genomic DNA was digested overnight with the combination
of restriction enzymes TaqI, BspLU11I, and BclI (Roche Diagnostics,
Indianapolis, IN), and subjected to the STA–polymerase chain reaction
(PCR) and SplinkBlunt-PCR protocol, as previously reported.24 After
electrophoresis on 1.2% of agarose gel, individual secondary PCR bands
were cloned into TOPO TA vector (Invitrogen, Carlsbad, CA) for sequencing.
Sequence analysis
Proviral insertion sites (PISs) were mapped by searching against Ensembl
and Celera Mouse Genome Database using the BLASTN algorithm.25
RT-PCR
Total RNA was extracted from tumor samples using TRIzol (Invitrogen),
followed by treatment with DNase I, according to the manufacturer’s
instructions. Reverse-transcription PCR (RT-PCR) was conducted using the
SuperScript II First Strand cDNA Synthesis system (Invitrogen), followed
by PCR using gene-specific primers, as reported previously.20 Sequences of
primers used in the RT-PCR for amplification of genes examined in this
study are available on request.
Southern blotting analysis
A total of 10 g genomic DNA was digested with the indicated restriction
enzymes and resolved on a 1.0% agarose gel, followed by standard blotting,
hybridization, and radioautography procedure.20 The pMIGR-Bcl11a con-
struct-specific probe and the cDNA probe specific for the Ing1 gene were
labeled with -32P–dCTP using the random priming labeling approach.20
Construction of pMIGR-Bcl11a, retrovirus production, and
establishment of stable transductants
Bcl11a cDNA (a gift from Dr Takuro Nakamura, The Cancer Institute,
Japanese Foundation for Cancer Research, Tokyo, Japan) was fused with
His tag by PCR and subcloned into the BglII-XhoI site of a retroviral
expression vector, pMIGR (a gift from Dr Juli Miller, The University of
Pennsylvania, Philadelphia, PA), to create pMIGR-Bcl11a, which expresses
both Bcl11a and enhanced green fluorescence protein (EGFP).26 Constructs
were verified by sequencing. pMIGR-Bcl11a and empty vector were used to
transfect 293T cells for production of vesicular stomatitis virus G (VSV-G)
pseudotyped retrovirus, as previously described.26 The retrovirus was used
to infect cultured cells in the presence of 4 g/mL polybrene. The
EGFP-positive cells were sorted from the population of transduced cells by
flow cytometry (BD Biosciences, San Jose, CA).
Bone marrow transduction and transplantation assay
Bone marrow cells were harvested from donor mice 5 days after they were
treated with 150 mg/kg 5-fluorouracil, as described previously.27 Cells were
stimulated for 24 hours with interleukin-6 (IL-6), IL-3, and stem cell factor (SCF)
before being infected with the indicated viruses in the presence of 2 g/mL
polybrene. Transduced bone marrow cells were intravenously injected into
lethally irradiated C57BL/6J.BoyJ mice at 106 cells per recipient mouse. Mice
were observed on a daily basis for any signs of disease.
Immunologic phenotyping and flow cytometry
As previously described,28 cells were incubated on ice in blocking buffer
containing CD16/32 Fc blocker for 15 minutes, before staining with
antibodies on ice for 25 minutes. Subsequently, cells were washed and
subjected to flow cytometry analysis using 4-color FACSCalibur flow
cytometer (BD Biosciences) following the manufacturer’s instruction. All
fluorochrome-conjugated antibodies were purchased from BD PharMingen
(San Diego, CA), and the applied dilutions of antibodies were optimized in
our laboratory. CD45.1–phycoerythrin (PE) and CD45.2–fluorescein isothio-
cyanate (FITC) were used to distinguish donor and recipient cellular origin.
Conjugated antibodies staining for Mac-1, Gr-1, T-cell receptor  (TCR-),
and B220 were used to examine the origin of cell lineages. Data were
analyzed using FlowJo 7.0 Software (TreeStar, Ashland, OR).
Cell growth assay
A total of 105 cells per well were seeded into 24-well plates in quadruplicate
in acid sphingomyelinase medium19 complemented with 10% WEHI-3–
conditioned medium, and cultured at 37°C in a 10% CO2 humidified
incubator. An aliquot of 10 L homogeneous cell suspensions was taken at
0, 24, and 48 hours, respectively, to count the cumulative cell number.
Western blot
Cells were washed with phosphate-buffered saline (PBS) and lysed in
Nonidet P-40 (NP-40) lysing buffer.21 Protein concentrations were deter-
mined using the Bradford method (Pierce Chemical, Rockford, IL). A total
of 40 g total protein was boiled for 5 minutes before electrophoresis on
10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) gels, and subsequently blotted to methanol-activated polyvinylidene
difluoride (PVDF) membrane (Bio-Rad, Hercules, CA). The blots were
blocked and incubated with the primary antibodies as follows: His probe
(1:2000; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti–
extracellular signal-regulated kinase 1 (ERK1; 1:1500; Santa Cruz Biotech-
nology), and mouse antibodies against indicated cell-cycle regulatory
proteins are available in the Cell Cycle I/II Sampler Kit (BD PharMingen).
After incubation with horseradish peroxidase (HRP)–conjugated secondary
antibodies, blots were developed by the enhanced chemiluminescence
detection system (GE Healthcare, Little Chalfont, United Kingdom) and
then exposed to the X-ray films.
Statistics
Student t tests were used to compare means of cell number between
different genotypes of immortalized hematopoietic cells. The Fisher exact
test was applied to determine whether there was difference in incidence of
Bcl11a-targeting PIS between leukemia with wild-type Nf1 and Nf1
deficiency. Differences between groups were considered significant at
values of P less than .05.
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Results
Identification of CISs of BXH-2 MuLV
We examined genomic DNA specimens derived from BXH-2 strain
AML, which are Nf1-intact (n  25) or Nf1-deficient (n  55). In
19 Nf1-deficient AMLs, the Nf1 gene was disrupted by murine
leukemia virus (MuLV) insertions within the Evi2 locus,12,29 and
36 AMLs were generated using Nf1 knockout mice (Figure 1).12,29
Somatic proviral insertions in these AML were isolated efficiently
with STA-PCR and SplinkBlunt-PCR that we have developed.24
We obtained 197 informative PISs, with 2.46 PISs recovered from
each tumor on average (Table S1, available on the Blood website;
see the Supplemental Materials link at the top of the online article).
We expect that this is close to full PIS recovery compared with the
number of PISs per BXH-2 tumor detected by Southern blotting
assay (data not shown).24,29
Mapping of these PISs using the Ensembl mouse genome
database uncovered 12 CISs, including 9 novel CISs (group I CIS
in Table 1) and 3 previously reported CISs (group II CIS in Table
1). For some PISs isolated only once in this screen, cross-reference
to other PIS profiles deposited in the Retrovirus Tagged Cancer
Gene Database (http://rtcgd.abcc.ncifcrf.gov/) resulted in the recog-
nition of 13 CISs (group IV CIS in Table 1). Similarly, 17 CISs
were identified where our single PISs hit known CISs (group V CIS
in Table 1). Interestingly, many CISs mapped to chromosomal
locations that are syntenic to sites of recurrent structural abnormali-
ties in human malignancies (Table S2).
To explore the biologic significance of the 40 new and known
CIS-associated genes (Table 1), the Ingenuity Pathway Analysis
program (http://www.ingenuity.com/) was used to produce molecu-
lar networks. The NF-B pathway was predicted with the highest
likelihood, organizing 14 (or 39%) of the total genes found in our
study. The second most probable pathway involved 9 candidate
genes, including Bcl11a. These data suggest that dysregulation of
the NF-B pathway and Bcl11a-associated pathway may contribute
to the development of AML.
Analysis of candidate leukemia genes
The Ahi1/Myb CIS represents the most frequent insertion site in our
screen. Fourteen proviral insertions with either orientation were
recovered immediately downstream to the Ahi-1 gene, also approxi-
mately 35 kb downstream to c-Myb (Figure S1), presumably
enhancing transcription of Ahi-1 and c-Myb. This finding highlights
the potential role of deregulation of Ahi-1 and c-Myb in
leukemogenesis.
Bcl11a and Spred2 were hit as often as Meis1 and Hoxa7/a9,
which have been strongly implicated in human myeloid leukemo-
genesis.30 Whereas we observed a similar pattern of insertions in
Nf1-deficient and Nf1-intact leukemias at most CISs, the PISs
targeting Bcl11a and Spred2 were all isolated from Nf1-deficient
AMLs (Table 1). Five PISs with sense or antisense orientation were
isolated from the first intron of Spred2, indicating that disruption of
normal transcription of Spred2 could cooperate with Nf1 deficiency
during formation of leukemia (Figure S2). Consistent with this
possibility, SPRED2 are thought to be a negative regulator of
RAS/ERK signal transduction,31 and expression of SPRED2 is
decreased in some cancers.
To further explore the putative association between Nf1 defi-
ciency and Bcl11a-targeting insertions, which turn out to overlap
with known Evi9 insertions, Southern blot analysis of 40 additional
Nf1 intact BXH-2 AMLs with a Bcl11a-specific probe were
performed, and we did not detect any evidence of proviral
insertions (P  .02; Figure S5). These data suggest that Evi9
insertions are enriched in the Nf1-deficient versus Nf1-intact AML
we studied, although they are probably not unique to Nf1 defi-
ciency. In addition to Bcl11a, 3 other genes flanking Evi9 were
predicted, tentatively designated as Evi9-PG1, Evi9-PG2, and
Evi9-PG3, respectively (http://www.ensembl.org/) (Figure 2A).
Strikingly, unlike the majority of reported CISs, our Bcl11a-
targeting insertions contain 5 PISs located within a narrow
chromosomal region of less than 1 kb, underlining a strong
correlation between insertions at Evi9 with leukemogenesis.
To uncover the gene(s) that is the potential biologic target of
proviral insertions at Evi9, we examined expression levels in
BXH-2 leukemia of surrounding genes by RT-PCR using gene-
specific primers. We could not detect any transcripts from Evi9-
PG1 and Evi9-PG3 in these tumors (Figure 2B). Evi9-PG2 is
expressed at a higher level in the Evi9 insertion-bearing leukemia
than others. Further analysis showed that Evi9-PG2 was only
523 bp in size, harboring a single exon without a predictable coding
frame. Thus, Evi9-PG2 could be a pseudogene, or possibly, a
noncoding RNA gene. Bcl11a expression could be observed at
different levels in 5 of 6 tumors. Sequencing confirmed the
specificity of the upper RT-PCR bands shown in Figure 2B (data
not shown). As expected, the highest expression level of Bcl11a
was detected in the Evi9 insertion-bearing leukemia only for which
RNA was available, suggesting that Bcl11a is up-regulated as a
consequence of Evi9 insertions.
Expression of Bcl11a in Nf1-deficient bone marrow cells leads
to leukemia
Our findings that (1) Evi9 is a frequent target by MuLV, (2) Evi9
occupies an exceptionally narrow window, (3) Evi9 is enriched in
Nf1-deficient tumor panel, and (4) Bcl11a appears to be the primary
target of Evi9 established Bcl11a as a strong candidate for
cooperation with Nf1 inactivation. In addition, Bcl11a has been
implicated in the development of human lymphocytic leuke-
mia.14,15,30 Therefore, we decided to investigate the role of Bcl11a
Figure 1. Strategy for collection of leukemia with intact or deficient Nf1 gene for
this study. Nf1/.MuLV indicates MuLV-infected Nf1-intact leukemia; Nf1/.MuLV,
MuLV-infected leukemia with engineered null Nf1 allele. Nf1Evi2.MuLV, MuLV-infected
leukemia with Nf1 disruption by proviral insertion into Nf1. * indicates that the
leukemias were produced previously by the laboratory of Dr Camy I. Brannan
(deceased) through multiple rounds of backcrossing Nf1-null mice onto the BXH-2
strain of mice.12,29 PIS indicates proviral insertion site; and CIS, common proviral
insertion site.
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in leukemogenesis using the bone marrow transduction and trans-
plantation assay (BMTT; Figure 3A).27 Donor bone marrow cells
were collected from C57BL/6 mice generated via a cross between
mice carrying a conditional mutant (floxed) allele of Nf1 and
heterozygous Nf1-null (Nf1Fcr/) mice also transgenic for a Cre
transgene driven by the Mx-1 promoter.32 Bone marrow from
wild-type Nf1 (Nf1/) C57BL/6 mice carrying the Mx1-Cre
transgene were used as a control. Wild-type and Nf1 mutant bone
marrow cells were transduced with either Bcl11a-expressing or
empty vector VSV-G–pseudotyped retrovirus, followed by trans-
plantation into lethally irradiated C57BL/6.BoyJ recipient mice
carrying the CD45.1 allele of the cell-surface marker CD45. This
allowed us to distinguish the origin of cells in transplant recipients.
Therefore, 4 groups of mice were obtained, including mice
Table 1. Candidate leukemia genes identified in this MuLV screen
CIS group*/Gene hit† Annotation
Tumor panel‡
Nf1 Evi2 Nf1
I
Edg3 Endothelial differentiation, sphingolipid G protein–coupled receptor, 3 0 1 1
ENS#1 Unknown 2 1 1
FLJ20186 Differentially expressed in FDCP 8 1 0 2
Ing1 Inhibitor of growth protein 1 1 1 1
Etnk1 Ethanolamine kinase 1 1 0 1
II
Bcl11a B-cell CLL/lymphoma 11A 0 3 2
Spred2 Sprouty protein with EVH-1 domain 2, related sequence 0 1 4
Pmaip1 Phorbol-12-myristate-13-acetate–induced protein 1 1 1 0
Jund1 Jun proto-oncogene–related gene d1 1 0 1
III
Ahi1/Myb WD domain and SH3 domain–containing gene 6 4 4
Hoxa7/a9 Homeobox A7/A9 2 0 2
Meis1 Myeloid ecotropic viral integration site 1 3 0 2
IV
Usp21 Ubiquitin-specific protease 21 1 0 0
Enah Enabled homolog 1 0 0
Tlr2 Toll-like receptor 2 1 0 0
Btbe3 Basic transcription element–binding protein 3 0 1 0
Sar1a GTP-binding protein Sar1a 1 0 0
Fgd3 Faciogenital dysplasia homolog 3 1 0 0
Pilrb Paired immunoglobulin-like type 2 receptor beta 0 0 1
Foxd1 Forkhead box protein D1 0 1 0
Gata2 GATA-binding protein 2 1 0 0
Olig2 Oligodendrocyte transcription factor 2 1 0 0
Wnt7a Wingless-type MMTV integration site family, member 7A 1 0 0
Ly86 Lymphocyte antigen 86 0 1 0
ENS#2 Unknown 0 0 1
V
ENS#3 Similar to eosinophil chemotactic cytokine 0 1 0
Nfkb1 Nuclear factor NF--B p105 subunit 1 0 0
Centg3 Centaurin, gamma 3 1 0 0
Dyrk1b Dual-specificity tyrosine-(Y) phosphorylation-regulated kinase 1b 1 0 0
Tbx21 T cell–specific T-box transcription factor T-bet 0 1 0
Lyl1 Lymphoblastomic leukemia 1 0 0
Cbfa2t3h Core-binding factor, runt domain, alpha subunit 2 1 0 0
PHF5A PHD finger protein 5A 0 0 1
Runx1 Runt-related transcription factor 1 0 1 0
Tcirg1 T-cell, immune regulator 1 0 1 0
Lin28 RNA-binding protein LIN-28 0 0 1
Emid2 EMI domain–containing protein 2 0 0 1
ATP5G2 ATP synthase, H transporting, mitochondrial complex, subunit C2 0 1 0
Ifngr1 Interferon-	 receptor 1 0 0 1
Atp5g2 ATP synthase lipid-binding protein, mitochondrial precursor 0 0 1
Vegfb Vascular endothelial growth factor B 0 0 1
Lmo2 LIM domain only 2 1 0 0
Akt1 v-akt murine thymoma viral oncogene homolog 1 0 1 0
*CIS group indicates the way CISs were identified for the corresponding genes. CISs that are composed of at least 2 insertions positioned within 20-kb pairs isolated in this
study, and no insertions (I), single insertions (II), or known CISs (III) have previously been reported. IV and V indicate single insertions isolated in this study for which known
single insertions (IV) or CISs (V) can be found.
†Gene hits indicate genes located nearby CISs, which were determined according to the annotation for the mouse genome (http://www.ensembl.org). ENS#1 indicates
ENSMUSG00000019986; ENS#2, ENSMUSG00000030553; and ENS#3, ENSMUSG00000010135.
‡Tumor panel denotes the genotype of leukemia from which the corresponding proviral insertions were recovered. Nf1 indicates tumors with intact Nf1 alleles;
Evi2, tumors with Nf1 alleles disrupted by Evi2 insertion; and Nf1, tumors with engineered null Nf1 allele. Values are the number of insertions isolated from each
genotype of leukemia.
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receiving Nf1-sufficient bone marrow cells, which had been
transduced with empty vector packaged retrovirus (Nf1(/).EV),
Nf1-sufficient bone marrow cells transduced with Bcl11a-
expressing retrovirus (Nf1(/).Bcl11a), Nf1-deficient bone mar-
row cells transduced with empty vector packaged retrovirus
(Nf1(Flox/Fcr).EV), and Nf1-engineered bone marrow cells trans-
duced with Bcl11a-expressing retrovirus (Nf1(Flox/Fcr).Bcl11a).
We administered polyI:polyC to all mice receiving these donor
marrow cells to induce recombination-mediated deletion of the
floxed allele by activating the Mx1-Cre transgene.32
Approximately 3 weeks after polyI:polyC treatment, engraft-
ment of donor cells was examined by performing PCR on genomic
DNA from peripheral blood cells collected retro-orbitally from
recipient mice. Primers specific to the floxed allele of Nf1 were
used (Figure S3A). The “WT” PCR band can be amplified from
peripheral blood cells with all 4 genotypes, whereas the floxed Nf1
allele–specific (“Flox”) and recombined Nf1 allele–specific (“Del”)
products can only be seen in peripheral blood cells derived from the
Nf1(Flox/Fcr).EV or Nf1(Flox/Fcr).Bcl11a group of mice, indicating not
only engraftment of donor bone marrow but also the occurrence of
recombination of the floxed Nf1 allele after polyI:polyC induction.
The presence of residual floxed allele may reflect incomplete Nf1
deletion mediated by polyI:polyC-induced Cre expression. Further-
more, with Fcr-null allele-specific primers, the “Fcr” band
can be observed in peripheral blood cells from mice receiving
Nf1(Flox/Fcr).Cre bone marrow, but not from mice receiving
Nf1(/).Cre cells (Figure S3), which confirms both engraftment of
donor cells and the expected genotype of bone marrow cells
received. Importantly, we were able to detect the Bcl11a-expressing
retroviral vector that was used for transduction in blood cells from
the Nf1(Flox/Fcr).Bcl11a group of mice (Figure S3C), demonstrating
successful retroviral delivery of Bcl11a into recipient mice. These
results suggest that bone marrow engraftment, recombination-
mediated deletion of Nf1, and Bcl11a delivery into recipient mice
had been achieved.
By 9 months after polyI:polyC induction, none of 10 mice of the
Nf1(/).EV group had become sick (Figure 3B). Two mice each
had died in the Nf1(/).Bcl11a (n  11) and Nf1(Flox/Fcr).EV (n  12)
cohorts (Figure 3B). By contrast, all 11 recipients that received
Nf1(Flox/Fcr) cells transduced with the Bcl11a virus became moribund
by 7 months after polyI:polyC treatment, with a median latency of
107.8 days (Figure 3B). A similar trend in latency of disease was
observed in an independent BMTT assay (data not shown). Most
sick Nf1(Flox/Fcr).Bcl11a mice had enlarged lymph nodes, liver, and
spleen (Table S4A). Visible metastases to the liver and kidney were
readily observed. Enlarged thymi were seen in 2 mice without
apparent abnormalities in other organs (Table S4A). Most mice
exhibited high white blood cell counts (Table S4B). Generally,
there was a decrease in the levels of hemoglobin and in the number
of red blood cells and platelets (Table S4B). Pathologic analysis
showed an increase in the number of immature myeloid or
lymphoid cells in peripheral blood and bone marrow of
Nf1(Flox/Fcr).Bcl11a mice. Spleen touch preps also displayed an
excessive infiltration of blast-like cells. Significantly, neoplastic
blast cells were found in multiple tissues, including bone marrow,
spleen, lymph node, liver, kidney, and thymus (Figure 3C),
indicating that normal tissue structures are effaced and replaced by
infiltrating tumor cells. In addition, a 3.7-kb band can be detected in
the enlarged lymph nodes and thymi by Southern blotting assay
using a construct-specific probe (Figure S4), indicating the pres-
ence of the Bcl11a-expressing construct in the affected tissues.
Furthermore, tumor cells isolated from 3 Nf1(Flox/Fcr).Bcl11a mice
were intravenously injected into 9 syngeneic C57BL/6J mice at
106 cells per mouse, 3 mice for each tumor. The recipient mice
became moribund within 6 to 10 weeks after inoculation of tumor
cells, with an apparent increase in white blood cell counts similar to
what has been observed in Nf1(Flox/Fcr).Bcl11a mice, which demon-
strates the transplantability of the disease developed in the BMTT
assay. Together, these data show that transplantation of Nf1-
deficient bone marrow cells overexpressing Bcl11a results in
aggressive hematologic malignancies in recipient mice.
Bcl11a-overexpressing, Nf1-deficient leukemia is of myeloid or
lymphoid lineage and derived from transduced donor cells
The origin of the tumor cells was determined by immunostaining
assay using antibodies specific for CD45.1 or CD45.2. The
majority of cells isolated from enlarged lymph node, spleen, and
thymus stained positive for CD45.2 (Figure 3D), indicating that
these tumor cells are primarily derived from transplanted donor
bone marrow. The cell lineage of origin of the leukemia was
Figure 2. Analysis of Bcl11a-targeting CIS. (A) The schematic
representation of the CIS-targeting Bcl11a. The solid arrows
indicate the relative position and orientation of isolated proviral
insertions at Evi9; the open arrows indicate the relative position
and transcriptional orientation of Bcl11a and 3 other predicted
genes; bracketed numbers, size (in kb) of genes. (B) Expression in
BXH-2 leukemia of Bcl11a and 3 other predicted genes nearby
Evi9 locus (Evi9-PG1, Evi9-PG2, and Evi9-PG3) was detected by
RT-PCR using gene-specific primers. The lanes marked “”
indicate AML samples with no Evi9 insertions; the lane marked “”
indicates 1 of the 5 AML samples with Evi9 insertions. Gapdh was
used as a loading control. NC indicates water in place of cDNA as
the template for PCR was set up as negative controls.
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defined by immunophenotyping with antibodies specific for my-
eloid or lymphoid lineage hematopoietic cells. Antibodies against
Mac-1, Gr-1, B220, or TCR- were used to profile lymph node and
bone marrow cells harvested from either healthy C57BL/6J mice or
mice transplanted with Bcl11a-transduced Nf1-deficient bone mar-
row cells. Although only scarce amounts of Mac-1– and Gr-1–
positive cells can be detected in normal lymph node, the number of
these cells was increased 11.33-fold plus or minus 4.86-fold in the
affected lymph nodes from 5 Nf1(Flox/Fcr).Bcl11a mice (Figure 3E),
indicating a myeloid lineage of these cells. Similarly, the bone
marrow collected from 4 Nf1(Flox/Fcr).Bcl11a mice displayed
4.60-fold plus or minus 1.82-fold higher cells staining positive for
TCR- than that harvested from normal mice (Figure 3F), suggest-
ing that these mice have developed T-cell leukemia. Therefore, we
conclude that Bcl11a-transduced Nf1-deficient bone marrow cells
cause leukemia in recipient mice, which is derived from transduced
donor cells and is of either myeloid or lymphoid lineage.
Bcl11a down-regulates p21Cip1 and promotes Nf1-deficient
cell growth
To investigate the mechanism underlying the cooperation between
Bcl11a and Nf1 deficiency in leukemogenesis, myeloid cell cultures
with Bcl11a overexpression and/or Nf1 ablation were examined for
their growth properties and differentiation potential. Retroviral
vectors carrying a His-tagged Bcl11a and an EGFP marker, or
EGFP alone, were used to transduce Nf1-intact or Nf1-null
Myb-immortalized myeloblast cell line hematopoietic cells12 (Fig-
ure 4A). EGFP-positive cells were then sorted to obtain 4 stably
transduced populations: Nf1-intact empty vector-transduced cells
(Nf1/.vector), Nf1-intact Bcl11a-transduced cells (Nf1/.Bcl11a),
Nf1-null empty vector-transduced cells (Nf1/.vector), and Nf1-
null Bcl11a-transduced cells (Nf1/.Bcl11a). To test functionality
of the Bcl11a-carrying construct, 293T cells were transiently
transfected and subjected to Western blotting assay using anti-His
antibody. Abundant Bcl11a protein was detected approximately at
the position of 170 kDa in Bcl11a-transfected cells, but not in
vector-transfected cells, indicating specific expression of Bcl11a
from the retroviral construct (Figure 4B).
After culture for 24 hours, the cumulative cell number of
Nf1/.Bcl11a cells was only slightly higher than those of 3 other
engineered cell lines (Figure 4C). However, this number increased
to 1.5-fold those of other cell lines at 48 hours of culture, indicating
that Nf1/.Bcl11a cells grew significantly faster (P  .05) than
control cells (Figure 4C). The enhanced growth potential of
Figure 3. Examination of oncogenic effect of Bcl11a
overexpression using the BMTT assay in mice.
(A) The BMTT scheme used in this study. (B) Survival
analysis on the BMTT-recipient mice, which received
Bcl11a- or empty vector (used as a negative control)–
transduced Nf1-intact (“Nf1(/).EV ” and “Nf1(/).Bcl11a”)
or Nf1-deficient bone marrow cells (“Nf1(Flox/Fcr).EV” and
“Nf1(Flox/Fcr).Bcl11a”). (C) Histopathologic examination of the
Bcl11a-induced leukemia in the recipient mice. Hematoxy-
lin and eosin staining. Representative images with mag-
nification of 60-fold are shown here. Bars represent
25 m. Slides were viewed with a Nikon Eclipse E600
bright light microscope (Nikon, Tokyo, Japan) using a
Nikon Plan Fluor 40
/0.75 objective lens. Images were
acquired using a Spot Insight digital camera (model 14.2,
Color Mosaic; Diagnostic Instruments, Sterling Heights,
MI), and were processed with Spotsoftware Advanced
(version 4.6 for Windows; Diagnostic Instruments) and
Adobe Photoshop version 7.0 software (Adobe Systems,
San Jose, CA). (D) Determination of donor origin of the
Bcl11a-induced leukemia developing in the BMTT-
recipient mice. Antibodies staining for CD45.1 or CD45.2
cell-surface molecules were used. (E,F) Determination of
cell-lineage origin of the Bcl11a leukemia developed in
the BMTT-recipient mice. Antibodies against Mac-1, Gr-1,
B220, or TCR- were used to stain lymph nodes and
bone marrows harvested from either healthy C57BL/6J
mice or mice transplanted with Bcl11a-transduced
Nf1-deficient bone marrow cells to collect evidence for
acute myeloid leukemia (E) or T-cell acute lymphoid
leukemia (F).
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Nf1/.Bcl11a cells was confirmed by MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt) assay (data not shown). This result suggests that
overexpression of Bcl11a can confer a growth advantage to
Nf1-deficient cells.
To examine the molecular basis of Bcl11a-stimulated prolif-
eration advantage, we examined the abundance of cell-cycle
regulatory proteins in these cell lines. There were no evident
changes between Nf1 status and/or Bcl11a transduction in the
basal level of 11 proteins examined, including Cdk4, cyclin A,
cyclin B, cyclin D1, cyclin D2, cyclin D3, p27, p21Cip1, PCNA,
p19Skp1, p36MAT1, Rb, and Erk (Figure 5D). Interestingly, when
challenged for 16 hours with 250 ng/mL doxorubicin, a DNA
intercalator and damaging agent, both Nf1/ (Figure 5E lane 3)
and Nf1/ (lane 7) cells displayed elevated p21Cip1 levels.
However, a marked decrease in the induced level of p21Cip1
was observed in Bcl11a-transduced Nf1/ or Nf1/ cells
(lane 4 and lane 8). These results suggest that Bcl11a over-
expression suppresses elevation of p21Cip1 level induced by
DNA damage.
Expression of BCL11A in human leukemia
To determine whether BCL11A could possibly be contributing to
human myeloid leukemia, we examined its expression in chronic
and acute forms of the disease. BCL11A expression levels in JMML
and chronic myelomonocytic leukemia were examined by RT-PCR.
As can be seen in Figure 6A, BCL11A expression is detected in
most patient samples from both types of diseases, although lower
than detectable in a few samples, which is consistent with the
possibility that BCL11A expression could make a positive contribu-
tion to these diseases. Interestingly, several of the other candidate
genes obtained from this insertional mutagenesis screen, including
EDG3, MEIS1, EKI, and DEF8, were expressed in these diseases
(Figure 5A).
A large-scale examination of gene expression in a cohort of
285 patients with AML has been performed using Affymetrix-
based microarray.33 Based on the overall gene expression profile,
these patients were grouped into 16 clusters using an unsupervised
cluster approach. Of note, 3 sets of BCL11A-specific probes all
generated comparable hybridization signals across these samples
Figure 4. Bcl11a promotes expansion of an Nf1-
deficient hematopoietic cell line and p21Cip1 down-
regulation. (A) Scheme for generating Nf1(/) or Nf1(/)
cell lines stably transduced with Bcl11a-expressing retro-
viral construct (Nf1/.Bcl11a and Nf1/.Bcl11a) or
with empty vector (Nf1/.vector and Nf1/.
vector) as negative controls. His6 indicates the protein
tag of 6 repeats of histidine. (B) Verification of the
Bcl11a-expressing vector by transient transfection of
293T cells followed by Western blotting assay. Anti-His
antibody was used. The double arrows indicate the
signal for Bcl11a. The single arrow indicates a nonspe-
cific (n.s.) signal. (C) Cumulative growth of the stable
Bcl11a- or vector-transduced Nf1(/) or Nf1(/) cells.
(D) The abundance of cell-cycle regulatory proteins in
stable Bcl11a or vector transductants. (E) p21Cip1 protein
level was determined in stable Bcl11a or vector transduc-
tants after doxorubicin treatment (Doxo) for 16 hours.
Representative results from 3 independent experiments
were shown here.
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(Figure 5B). This microarray analysis revealed that BCL11A
displayed variant abundance of transcripts in AML (Figure 5B).
More interestingly, patients with high expression levels of BCL11A
were mostly segregated into 2 of 16 clusters: cluster 1 and cluster
10 (Figure 6B), whereas other groups and normal bone marrow
cells showed low expression of BCL11A. Cluster 10 is associated
with a poor outcome, and with monosomy 7, which is also common
in JMML and in cases of JMML that transform to AML. The
association of BCL11A level with poor outcome of patients in
cluster 10 indicates that BCL11A could be up-regulated in this
subset of AML and might contribute to these diseases. However,
patients in cluster 1 do not show a poor prognosis33; even many of
patients in this group also carry MLL translocations. Genetic
complexity of AML and gene expression–based classification of
patients could obscure the effects of certain genetic lesions on the
outcome of patients. Other factors, such as monosomy 7 seen in
cluster 10, may also contribute to the worse outcome of patients.
Discussion
In this study, we have identified a dozen novel CISs, some of which
probably cooperate with Nf1 deficiency in the development of
leukemia. We have, for the first time, demonstrated that Bcl11a acts
as an oncogene and causes leukemia in the absence of Nf1 in mice,
perhaps through suppression of p21Cip1 induction and thereby
promotion of cell growth. Our results also suggested that expres-
sion of BCL11A may contribute to leukemogenesis in certain
groups of AML patients.
An association of BCL11A with hematologic malignancies
has been indicated in the literature. Abnormalities involving
BCL11A have been detected in a variety of B-cell malignancies
in humans.14,15,34 The chromosomal region containing the BCL11A
gene is also recurrently rearranged in other human tumors.35
However, it has been controversial whether BCL11A is the real
affected gene responsible for the diseases.14,34 Furthermore, in 2
of 209 BXH-2 myeloid leukemia, proviral insertion sites were
found to be located within the first intron of Bcl11a and resulted
in increased expression, instead of disruption, of Bcl11a.30
Bcl11a has also been reported to transform NIH 3T3 in foci
formation assay.36 These data support a role of Bcl11a as a
dominantly acting proto-oncogene. On the other hand, by
generating Bcl11a knockout mice, Liu et al suggested that
Bcl11a is critical for B-cell and alpha/beta T-cell development,
but not for macrophage-granulocyte and erythroid lineages.13
Figure 5. BCL11A expression in human leukemia. (A) BCL11A
expression in human chronic myelomonocytic leukemia and juvenile
myelomonocytic leukemia was detected by RT-PCR. NC indicates
water in place of cDNA as template for PCR. GAPDH was used as a
loading control. The JMML samples are found to carry mutations in
KRAS (no. 1) or PTPN11 (nos. 2-7), or wild type for both genes (no.
8). (B) Gene expression profiling in a large cohort of human acute
myelogenous leukemia. Results using a set of 3 probes for BCL11A
are displayed. Probe nos. 1, 2, and 3 indicate probe sets,
210347_s_at, 219497_s_at, and 219498_s_at, respectively. Clusters
of AML showing increased level of BCL11A are noted (clusters 1 and
10).
Bcl11a
p21Cip1
Bcl6
p53
Cell cycle
Nf1
Ras
Anti-cancer
SIRT1 
Figure 6. The model for cooperative oncogenesis between Bcl11a and Nf1
deficiency. The thickened lines indicate the major linkage of Bcl11a-Nf1 loss
cooperation to leukemogenesis that was identified in this study. The arrows indicate a
stimulatory relationship; perpendicular lines, suppression. One major function of Nf1
is to negatively regulate Ras activity, and Nf1 deficiency leads to hyperactivation of
Ras.66,67 Ras activation alone can trigger cell growth arrest and senescence.49
However, this effect may be attenuated by an increase in Bcl11a signal, which results
in suppression of p21Cip1 induction and, consequently, release of its control over cell-
cycle progression, as discovered in this study. Bcl11a may directly repress Cdkn1a
transcription or indirectly through p53 mediated by BCL636,68 or SIRT1.64,65,69
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Paradoxically, transplantation of Bcl11a knockout mice fetal
liver cells resulted in T-cell leukemia originated from recipient
mice, suggesting that Bcl11a may be a non–cell autonomous
T-cell tumor suppressor gene.13 Moreover, another member of
Bcl11 family, Bcl11b, has been suggested to be a tumor
suppressor gene, acting via an increase in resistance to DNA
damage.37,38 Thus, it has been left unclear whether Bcl11a
functions as an oncogene or tumor suppressor gene, under what
conditions, and in what manner Bcl11a can cause tumor.
We found that proviral insertions located downstream of Bcl11a
concentrated in an Nf1-deficient AML panel. Consequently, expression
of Bcl11a was up-regulated, presumably through long-range activation
effect of retroviral insertion.39 Given that no other affected genes around
these insertions were identified, these data strongly indicate Bcl11a as an
oncogene in Nf1-deficient myeloid leukemia. Indeed, our findings of the
ability of Bcl11a overexpression in Nf1-deficient bone marrow cells to
induce mouse leukemia, combined with our observation of BCL11A
dysregulation in certain subsets of human AML, have established that
Bcl11a functions as an oncogene in both myeloid and lymphoid
lineages, in a cell autonomous manner, and in the absence of Nf1
function. These results indicate that Bcll1a may have a multilineage
effect. The tumorigenicity of an oncogene in multiple cell types has been
observed previously.40-42 It is possible, however, that the murine stem
cell virus–long terminal repeat used to express Bcl11a in our study could
create a bias toward T-cell malignancy.43,44 Transgenic models using
different promoters to express Bcl11a would provide a different
approach to look at the lineage tropism of Bcl11a oncogenicity. Our
study also suggests whether Bcl11a is implicated in human neoplasias
other than lymphoid diseases will need to be examined.
There are indications that secondary genetic events are
needed for the development of leukemia initiated by Nf1
deficiency. Although the cooperation of Nf1 deficiency with
other genetic alterations has been proposed or attempted,29,45,46
convincing evidence is still lacking. Our results suggest the
existence of a strong synergetic effect of Bcl11a up-regulation
and Nf1 deficiency. This cooperation has not been revealed by
any other kind of PIS studies, including a recent extensive
computational analysis of PISs deposited in the Retrovirus
Tagged Cancer Gene Database.47 Recent studies suggested that
defects in DNA repair genes influence NF1 tumor progression in
mice and humans, presumably by inactivating normal allele of
NF1.46,48 We found that formation of leukemia with Nf1 biallelic
inactivation and Bcl11a overexpression was markedly acceler-
ated, suggesting that other genetic lesions may contribute more
significantly to the observed progression of NF1 tumor than loss
of heterozygosity of NF1. In addition, myeloproliferative disor-
der (MPD) can progress to AML; however, there are no solid
experimental data explaining the progression of MPD into AML
in the context of JMML or other NF1-associated myeloid
diseases. It has been shown that mice with Nf1 deficiency in
hematopoietic cells develop an MPD-like disease.11,12,32 Based
on these studies, our genetic study has provided a mouse model,
clearly demonstrating that Nf1-associated MPD, on acquisition
of Bcl11a dysregulation, is capable of progression into AML.
Combined with previously published work, we propose a model of
our current understanding of the Bcl11a/Nf1 deficiency cooperation.
Dysregulated Ras signaling has been the only known major downstream
effect of Nf1 deficiency in cancer so far. Ras activation alone in primary
fibroblasts could trigger p53/p16-dependent growth arrest and senes-
cence.49 These cell-defensive responses, however, during the develop-
ment of leukemia could be overcome through the acquired enhancement
of Bcl11a expression, which could result in suppression of p21Cip1
induction. The role of p21Cip1 in multiple aspects of hematopoiesis has
been documented.50-59 p21Cip1 induction is correlated with reduced
colony formation and cell-cycle arrest of hematopoietic progenitor cells
or leukemic cells.50-53 p21Cip1 loss cooperates with AML1-ETO in
leukemogenesis and accelerates the onset of mouse mammary tumor
virus H-ras–induced tumors.59,60 Interestingly, N-ras oncogene up-
regulates p21Cip1 in hematopoietic cells, but Ras does not induce growth
arrest in p21Cip1-null fibroblasts, and p21Cip1 loss can rescue Ras-driven
anchorage independence and tumorigenesis.56,61,62 The p21Cip1 suppres-
sion by Bcl11a could be as a result of direct repression of Cdkn1a
transcription by Bcl11a. We have noticed that the Cdkn1a gene has
2 potential Bcl11a-binding sites in its promoter region, which supports
the assumption of direct mode of suppression. An experimental valida-
tion of Cdkn1a as a direct transcriptional target of Bcl11a is warranted.
The suppressive effect of Bcl11a could also be exerted indirectly
through other intermediate proteins.36,63-65 Thus, it is probable that Nf1
deficiency in hematopoietic cells may cause the similar effects as Ras
activation, which requires cooperation with other genetic abnormalities,
such as Bcl11a overexpression, to develop further into aggressive
forms of leukemia.
We expect that the establishment of Bcl11a’s oncogenic role
will stimulate further understanding of its biologic function and
molecular mechanisms in disorders and eventually allow for the
development of therapeutic strategies in the treatment of Bcl11a-
relevant diseases.
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